1-8 of 8
Hongxiang Hu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Free
Ciara Louise Freeman, Sarah Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Johanna Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel
Journal: Blood
Blood (2025) 146 (Supplement 1): 4079.
https://doi.org/10.1182/blood-2025-4079
Published: 2025
Journal Articles

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Free
Susan Bal, Luciano Costa, Nizar Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safiyyah Ziyad, Sham Mailankody
Journal: Blood
Blood (2025) 146 (Supplement 1): 5807.
https://doi.org/10.1182/blood-2025-5807
Published: 2025
Journal Articles

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Free
Safiyyah Ziyad, Kristina Jordahl, Hongxiang Hu, Ethan Thompson, Susan Bal, Myo Htut, Larry Anderson, Tara Gregory, Luciano Costa, Omar Nadeem, Naomey Sarkis, Ziyan Guo, Wei-Ming Kao, Allison Kaeding, Shari Kaiser, Michael Burgess, Jesús Berdeja
Journal: Blood
Blood (2025) 146 (Supplement 1): 2223.
https://doi.org/10.1182/blood-2025-2223
Published: 2025
Journal Articles

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Free
Eyal Lebel, Ahmed Abdulgawad, Stefania Bramanti, Gonzalo Garate, Phoebe Joy Ho, Mikko Keränen, Yaël Cohen, Maja Vase, Amit Khot, Ida Bruun Kristensen, Richard LeBlanc, Cindy Lee, Wojciech Legiec, Hila Magen, María-Victoria Mateos, Danielle Oh, Ludek Pour, Natalia Schutz, Alexandros Spyridonidis, Katja Weisel, Jan Zaucha, Sarah Larson, Asya Varshasvsky, Kimberly Grazioli, Debashree Basudhar, Hongxiang Hu, Ya Meng, Lamis Eldjerou, Susan Bal, Simon Harrison, Rakesh Popat, Marc Raab, Paula Rodriguez-Otero
Journal: Blood
Blood (2025) 146 (Supplement 1): 2302.
https://doi.org/10.1182/blood-2025-2302
Published: 2025
Journal Articles

BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study

Free
Courtney DiNardo, Eduardo Rodríguez-Arbolí, Jordi Esteve, Olga Salamero, Andrew Brunner, Maria Calbacho, Daniel Deangelo, Noelia Purroy, Josiana Limones, Carmen Jimenez, Hongxiang Hu, Griff McTume, Maria Dolores Jimenez, Javier Estrada, Yili Qian, Soraya Carrancio, Thomas Prebet, Timothy B. Campbell, Michael Pourdehnad, Geoffrey Uy
Journal: Blood
Blood (2025) 146 (Supplement 1): 1642.
https://doi.org/10.1182/blood-2025-1642
Published: 2025
Journal Articles

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Free
Susan Bal, Myo Htut, Jesús G. Berdeja, Larry D Anderson, Jr., Adriana Rossi, Tara Gregory, Thomas G Martin, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Omar Nadeem
Journal: Blood
Blood (2024) 144 (Supplement 1): 2069.
https://doi.org/10.1182/blood-2024-203279
Published: 2024
Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Free
Susan Bal, Larry D Anderson, Jr., Omar Nadeem, Jesús G. Berdeja, Adriana Rossi, Tara Gregory, Mehmet Hakan Koçoğlu, Thomas G Martin, Daniel N. Egan, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Myo Htut
Journal: Blood
Blood (2024) 144 (Supplement 1): 922.
https://doi.org/10.1182/blood-2024-201356
Published: 2024
Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Free
Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Jr., Hakan Koçoğlu, Tara Gregory, Adriana C Rossi, Tom Martin, Daniel N. Egan, Luciano Costa, Hongxiang Hu, Yanping Chen, Shaoyi Li, Lisa M. Kelly, Naomey Sarkis, Safiyyah Ziyad, Wei-Ming Kao, Allison June Kaeding, Michael R. Burgess, Jésus G Berdeja
Journal: Blood
Blood (2023) 142 (Supplement 1): 219.
https://doi.org/10.1182/blood-2023-181857
Published: 2023